Products
Online Inquiry
BP-1-102
Cat. No.:
OB0225WX-2704
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
BP-1-102 is an orally bioavailable STAT3 inhibitor that binds the protein with a Kd of 504 nM and effectively disrupts pTyr peptide interactions and STAT3 activation within the 4-6.8 micromolar range.
Synonym:
1334493-07-0; 4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid; 4-(N-(4-cyclohexylbenzyl)-2-((2,3,4,5,6-pentafluoro-N-methylphenyl)sulfonamido)acetamido)-2-hydroxybenzoic acid; 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid; 4-{N-[(4-cyclohexylphenyl)methyl]-2-(N-methyl-2,3,4,5,6-pentafluorobenzenesulfonamido)acetamido}-2-hydroxybenzoic acid; STAT3 Inhibitor XVIII
CAS No.:
1334493-07-0
Compound CID:
53388144
Formula:
C29H27F5N2O6S
Formula Weight:
626.59
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BP-1-102 is used in signal transduction research as a potent and selective STAT3 inhibitor targeting the SH2 domain to investigate the inhibition of STAT3 dimerization, DNA binding, and gene transcription.
Library Information
Target:
STAT
Receptor:
STAT3
Pathways:
JAK/STAT
Plate Number:
L6700-09
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
100 mg/mL; 159.59 mM
ALogP:
5.979
HBA_Count:
4
HBD_Count:
1
Rotatable Bond:
9
